GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (NAS:LUMO) » Definitions » FCF Yield %

Lumos Pharma (Lumos Pharma) FCF Yield % : -145.67 (As of May. 17, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Lumos Pharma's Trailing 12-Month Free Cash Flow is $-31.10 Mil, and Market Cap is $20.62 Mil. Therefore, Lumos Pharma's FCF Yield % for today is -145.67%.

The historical rank and industry rank for Lumos Pharma's FCF Yield % or its related term are showing as below:

LUMO' s FCF Yield % Range Over the Past 10 Years
Min: -148.31   Med: -25.02   Max: 11.79
Current: -145.67


During the past 13 years, the highest FCF Yield % of Lumos Pharma was 11.79%. The lowest was -148.31%. And the median was -25.02%.

LUMO's FCF Yield % is ranked worse than
89.08% of 1557 companies
in the Biotechnology industry
Industry Median: -14.1 vs LUMO: -145.67

Lumos Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -895.04%.


Lumos Pharma FCF Yield % Historical Data

The historical data trend for Lumos Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma FCF Yield % Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.63 -7.76 -51.24 -89.27 -120.68

Lumos Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.08 -135.82 -100.77 -119.76 -114.77

Competitive Comparison of Lumos Pharma's FCF Yield %

For the Biotechnology subindustry, Lumos Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's FCF Yield % falls into.



Lumos Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Lumos Pharma's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-31.095 / 25.7661408
=-120.68%

Lumos Pharma's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-7.393 * 4 / 25.7661408
=-114.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumos Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Lumos Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (Lumos Pharma) Business Description

Traded in Other Exchanges
N/A
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.
Executives
David B Karpf officer: Chief Medical Officer 1360 WILLOW ROAD #100, MENLO PARK CA 94025
Aaron Schuchart officer: Chief Business Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Richard J Hawkins director, officer: Chief Executive Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Emmett Cunningham director C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Kevin M. Lalande director 201 WEST 5TH STREET, AUSTIN TX 78701
John C. Mckew officer: Chief Scientific Officer C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756
Deerfield Mgmt Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Bradley J Powers officer: Principal Executive Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Lori D Lawley officer: Principal Accounting Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Ernest Iii Talarico director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010